WAVE Life Sciences (WVE) to Release Quarterly Earnings on Thursday

WAVE Life Sciences (NASDAQ:WVE) will likely be issuing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $7.45 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last posted its earnings results on Wednesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.21. The business had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. On average, analysts expect WAVE Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

WAVE Life Sciences Stock Down 0.9%

Shares of NASDAQ WVE opened at $5.74 on Thursday. The firm’s 50-day moving average price is $6.07 and its 200-day moving average price is $9.39. The company has a market cap of $1.10 billion, a PE ratio of -5.42 and a beta of -1.29. WAVE Life Sciences has a 52-week low of $5.02 and a 52-week high of $21.73.

Analyst Upgrades and Downgrades

WVE has been the topic of a number of research analyst reports. Wells Fargo & Company increased their price objective on shares of WAVE Life Sciences from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Citigroup cut their target price on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, May 4th. HC Wainwright reiterated a “buy” rating on shares of WAVE Life Sciences in a research note on Thursday, June 11th. Truist Financial began coverage on WAVE Life Sciences in a report on Wednesday, April 29th. They set a “buy” rating and a $15.00 price target on the stock. Finally, New Street Research set a $13.00 price target on WAVE Life Sciences in a research note on Thursday, June 11th. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.41.

Institutional Trading of WAVE Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. Hsbc Holdings PLC raised its position in WAVE Life Sciences by 52.1% in the fourth quarter. Hsbc Holdings PLC now owns 16,990 shares of the company’s stock worth $291,000 after acquiring an additional 5,823 shares during the period. Virtu Financial LLC purchased a new stake in shares of WAVE Life Sciences in the 4th quarter worth $457,000. Invesco Ltd. raised its holdings in WAVE Life Sciences by 27.5% in the 4th quarter. Invesco Ltd. now owns 179,932 shares of the company’s stock worth $3,059,000 after purchasing an additional 38,806 shares during the period. Voloridge Investment Management LLC bought a new position in WAVE Life Sciences in the 4th quarter worth $12,278,000. Finally, Squadron Capital Management LLC purchased a new position in WAVE Life Sciences during the fourth quarter valued at $2,975,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.